Last verified: April 21, 2026 · Caremark 4774-C confirmed · NovoCare pricing confirmed · CMS Bridge confirmed
Insurance Guide · April 21, 2026
Does CVS Caremark Cover Wegovy? What Your Plan Actually Pays in 2026
Last reviewed:
By The RX Index editorial team — a pricing intelligence and comparison resource for GLP-1 telehealth providers
Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.
Short answer: sometimes. As of July 1, 2025, Wegovy is the preferred GLP-1 for weight loss on CVS Caremark’s Standard Control, Advanced Control, and Value template formularies, and it stays preferred through 2026.¹ But “preferred” is not the same as “covered on your plan.” Whether CVS Caremark covers Wegovy for you depends on three layers stacked on top of each other: the Caremark formulary, your employer’s benefit design, and your prior authorization outcome. Caremark has said about one-third of its employer-sponsored book of business has no weight-loss drug coverage at all.²
CVS Caremark is a pharmacy benefit manager. Final coverage depends on your specific plan.
Find your situation fast
| If your situation looks like this… | You’re probably here |
|---|---|
| Portal says “covered, prior authorization required” | Likely yes — if your plan includes obesity coverage and your chart supports the criteria. PA requirements → |
| PA was approved but the pharmacy quoted a huge number | Cost-sharing or deductible issue, not a clinical one. Approved but expensive → |
| HR or the portal says your plan excludes weight-loss drugs | Likely no for obesity use — but alternative indications or cash-pay paths may work. Plan excludes it → |
| You’re on Medicare | Different 2026 rules apply. Don’t use commercial-plan logic. Medicare → |
Don’t want to navigate phone trees? Ro’s free GLP-1 Insurance Coverage Checker contacts your plan and sends you a personalized coverage report.
Check my Wegovy coverage on Ro →Free. No commitment to see the result.
The short answer: does CVS Caremark cover Wegovy?
CVS Caremark is the pharmacy benefit manager (PBM) that administers drug benefits for your insurer or employer. On Caremark’s standard templates — Standard Control, Advanced Control, and Value — Wegovy is the preferred GLP-1 for weight loss, and Caremark has publicly held that position into 2026 with no new GLP-1 formulary changes announced for the January 2026 update.⁷ Your specific plan still decides the rest.
This is why two coworkers with identical CVS Caremark ID cards can get completely different answers when they call. It’s not a glitch — it’s the structure. The employer decides whether weight-loss medications are a covered benefit at all. Caremark administers whatever the employer decided. Two people at different companies, or even two plans at the same company, can have opposite outcomes.
One honest admission, up front: we can’t tell you whether your plan covers Wegovy. Nobody writing about this query can — including the pages currently ranking above this one. Your employer’s benefit design is the final word, and the only way to know for certain is to verify it yourself. The good news: that takes five minutes.
What CVS Caremark publicly confirms about Wegovy right now
On the public side of the wall, Caremark has confirmed enough to answer most of what you actually want to know: Wegovy is preferred on the three most-used template formularies, the current PA policy (4774-C) requires BMI ≥30 or ≥27 with a qualifying comorbidity plus documented participation in a six-month comprehensive weight-management program, Wegovy tablets and injections are both in the criteria, and Caremark has said there are no new GLP-1 formulary changes for the January 2026 update.⁷
CVS Caremark Wegovy Coverage Verification Matrix
The one-page reference that separates what’s publicly true from what only your plan can tell you.
| Factor | What the public source says | What it means in practice | What still needs your plan’s verification |
|---|---|---|---|
| Formulary status¹ | Wegovy preferred on Standard Control, Advanced Control, and Value formularies; Zepbound removed July 1, 2025. | Favorable starting position for most commercial members. | Whether your employer uses a template or custom formulary that overrides it. |
| Plan-dependence⁸ | Caremark’s own member pages say drug coverage and PA rules depend on the member’s plan and formulary. | “Preferred” ≠ “your plan covers it.” | Your exact tier, copay, deductible, step therapy, and any plan-level exclusions. |
| Coverage-gap reality² | ~1/3 of lives in Caremark’s employer-sponsored book have no weight-loss medication coverage. | A favorable Wegovy strategy still leaves many members uncovered. | Whether your employer specifically opted into obesity-medication coverage. |
| Adult initial PA criteria⁴ | 4774-C: age ≥18, reduced-calorie diet + physical activity, 6-month comprehensive weight-management program, BMI ≥30 or ≥27 with qualifying comorbidity. | Missing documentation causes more denials than failing criteria. | How your prescriber documents the program, BMI, and diagnosis codes. |
| Renewal criteria⁴ | After ≥3 months at stable maintenance dose: ≥5% baseline weight loss or maintenance of that loss. | Renewal denials are often a chart problem, not a clinical failure. | Whether your provider’s notes clearly show baseline and current weight. |
| Tablet + pen both in criteria⁴ | Current 4774-C includes both Wegovy injection and Wegovy tablets. | Pages treating Wegovy as injection-only are already stale. | Whether your plan treats tablet and pen identically on tier, quantity, and PA. |
| Separate clinical pathways⁴ | Public criteria include weight-loss, cardiovascular risk reduction (injection), and MASH (injection, noncirrhotic F2–F3 fibrosis). | If weight-loss coverage is excluded, a different FDA-approved indication may change the answer. | Whether your diagnosis genuinely satisfies that separate pathway. |
| Optional $200 copay tier (2026)⁵ | Caremark’s 2026 GLP-1 outlook describes an optional up-to-$200/month tier for the weight-management category. | A benefit-design option clients can opt into — not a default. | Whether your employer selected that option and how it interacts with your out-of-pocket max. |
| Medicare 2026 handling⁶ | CMS Medicare GLP-1 Bridge runs July–December 2026, $50 flat copay, outside normal Part D flow, no coupons allowed on Bridge claims. | “Caremark covers it” is the wrong frame for most Medicare readers. | Bridge eligibility and 2027 access via BALANCE opt-in. |
| Fastest PA method⁹ | Electronic PA (ePA) is 2–3× faster than phone/fax; some automated decisions in under 6 seconds. | Telling your prescriber to use ePA materially shortens the wait. | Whether your prescriber’s EHR supports ePA for Caremark. |
Two takeaways: the public Caremark system favors you more than most pages suggest. The biggest variable isn’t Caremark — it’s your employer.
Ro’s insurance concierge contacts your plan and returns a personalized coverage report.
How to check your CVS Caremark Wegovy coverage in 5 minutes
The fastest self-check is Caremark’s Check Drug Cost & Coverage tool inside your member portal at caremark.com — it tells you whether Wegovy is covered on your plan and your estimated copay, specific to your deductible status.⁸ Then call the member services number on the back of your ID card with the four-question script below. Total time: about five minutes.
Step 1 — Check Drug Cost & Coverage (2 minutes)
Log into caremark.com (or the Caremark app) and use the Check Drug Cost & Coverage tool. Search “Wegovy.” The tool returns your plan’s coverage status, your tier, your estimated member cost at the dose you enter, and any notes like “PA required” or “step therapy.” If you have a prescription, enter the exact strength and quantity — the estimate can change by dose. Screenshot the result. That screenshot is your first piece of documentation if you need to escalate.
Step 2 — Call member services with this script
Call the number on the back of your insurance card. When you reach a person, ask:
- (1) Does my specific employer plan cover weight-loss medications, specifically Wegovy (semaglutide) — injection and tablet?
- (2) What tier is Wegovy on for my plan, what’s my estimated copay at each strength, and does my deductible apply first?
- (3) Does my plan require prior authorization, step therapy, or participation in a weight-management program — and are any of those in addition to Caremark’s standard 4774-C criteria?
- (4) Can I receive this coverage determination in writing — by email, in my member portal, or in a plan document?
Log the representative’s name, call reference number, and date. For question 2, if they say “it depends on the PA outcome,” press for the tier and copay if the PA is approved — that’s the number you need.
Step 3 — When the answer doesn’t match, the plan wins
If caremark.com says one thing and member services says another, the employer-specific plan document is the final word. Ask HR for your plan’s Summary of Benefits and Coverage (SBC) and the prescription drug formulary, or a link to both in your benefits portal. Once you have the written answer, you can stop guessing and move to the PA step — or to one of the alternative paths if your plan excludes the category.
No commitment. Ro will tell you whether a PA is worth submitting on your plan.
CVS Caremark Wegovy prior authorization: what’s actually required
Under Caremark’s public PA policy (document 4774-C), adult weight-loss approval requires age 18 or older, use alongside a reduced-calorie diet and increased physical activity, six months in a documented comprehensive weight-management program, and either BMI ≥30 or BMI ≥27 with at least one qualifying weight-related comorbidity (hypertension, type 2 diabetes, or dyslipidemia).⁴ Renewals require ≥5% baseline weight loss or maintenance of that loss after at least three months at a stable maintenance dose.⁴ The criteria sound simple. What trips people up is the documentation.
The adult initial-approval criteria, in plain language
- 1Age 18 or older. Separate pediatric criteria exist for ages 12–17.
- 2Use with lifestyle changes. The prescription must explicitly pair Wegovy with a reduced-calorie diet and increased physical activity.
- 3Six months in a comprehensive weight-management program. This is the single most common documentation gap. “Comprehensive” means structured diet, exercise, and behavioral counseling — not “I’ve been trying to eat less.” Your doctor needs chart notes showing the program, the provider or program name, and that it spans at least six months.
- 4The BMI rule. BMI ≥30 alone clears the bar. If your BMI is between 27 and 30, you need at least one qualifying comorbidity — hypertension, type 2 diabetes, or dyslipidemia.
Label-based safety considerations
Wegovy’s FDA label directs that Wegovy not be used if you or anyone in your family has a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and not to use Wegovy with other semaglutide-containing products or any other GLP-1 receptor agonist.¹⁰ These are prescribing safety notes — not Caremark-specific PA checklist items.
What makes a PA packet move faster
Have these ready before your prescriber’s office submits, so nothing bounces back:
- • Current height, weight, and BMI documented within the last 30 days.
- • Diagnosis codes for obesity (and any qualifying comorbidities) clearly in the chart.
- • Six-month comprehensive weight-management program history — program or provider name, dates, and what was covered (diet, exercise, behavioral counseling).
- • Any prior weight-loss medication trials documented with drug name, duration, and outcome.
- • A Letter of Medical Necessity, especially if your BMI or documentation is near the edge of a criterion.
- • Confirmation you’re not taking another GLP-1 or semaglutide product (labeling-based).
Submit via ePA, not fax
Caremark’s own pages confirm that electronic prior authorization (ePA) gets determinations two to three times faster than phone or fax, with some clean automated decisions delivered in under six seconds.⁹ Ask your prescriber’s office specifically: “Can you submit this via electronic prior authorization through Caremark, not fax?” If they say no, CoverMyMeds and Surescripts both integrate with Caremark’s ePA system for most major EHRs. That one request can take you from a multi-week wait to a same-week answer.
Renewals, Wegovy tablets, and the CV and MASH pathways most pages miss
The renewal rule that catches people off guard
At your first renewal, Caremark’s public criteria require that you’ve been on a stable maintenance dose for at least three months and have either lost at least 5% of your baseline body weight or maintained that 5% loss.⁴ If your doctor’s chart doesn’t clearly show your baseline weight from before Wegovy started and your current weight, the renewal gets flagged even if you’ve actually hit the target. Tell your prescriber at your first follow-up visit: “Please document my baseline weight and my current weight with dates, for my Caremark continuation paperwork.” It’s a 30-second ask that prevents a two-week hold on your refill.
Wegovy tablets are in the same PA policy as the pen
The Wegovy oral tablet launched in January 2026, and Caremark’s current 4774-C criteria include both the injection and the tablet in the same policy.⁴ What that means in practice depends on your plan — you should not assume your plan treats them identically. The tablet and injection can land on different tiers, have different quantity limits, or follow different PA durations under plan-level customization. Verify both forms with the Check Drug Cost & Coverage tool if you’re considering the pill. Self-pay pricing through NovoCare Pharmacy for the tablet: $149/month for 1.5 mg or 4 mg (4 mg at $149/month through August 31, 2026, then $199/month), and $299/month for 9 mg and higher doses.³
The cardiovascular risk reduction pathway
Wegovy injection is FDA-approved to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease plus obesity or overweight. Caremark’s 4774-C policy includes a separate PA pathway for this indication. The criteria are stricter than the weight-loss pathway:⁴
- • Wegovy injection only (not tablet).
- • Established cardiovascular disease: prior myocardial infarction, prior stroke, or symptomatic peripheral artery disease.
- • BMI ≥27.
- • Used alongside a reduced-calorie diet and increased physical activity.
- • Patient does not have type 2 diabetes — Ozempic is indicated for CV risk reduction in patients with T2DM, so the CV pathway for Wegovy specifically excludes them.
- • Patient is on guideline-directed management and therapy (GDMT) for cardiovascular disease, or has a documented clinical reason not to be.
This matters for readers whose employer plan excludes “weight-loss medications” specifically but covers cardiovascular medications broadly. Talk to your cardiologist or primary care doctor about whether your clinical history fits.
The MASH pathway
Wegovy injection (not tablet) is also included in Caremark’s PA criteria for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) with moderate to advanced liver fibrosis (stages F2 to F3).⁴ This is a separate pathway not tied to the weight-loss benefit category. It’s a narrower fit, but worth asking your gastroenterologist or hepatologist about if your plan excludes obesity use.
Why an “approved” Wegovy PA can still leave you with a huge bill
This is the hidden trap most pages skip. A Caremark PA approval only confirms that the medication is clinically authorized — it says nothing about how much you’ll pay. If the pharmacy quotes you $1,000+ after an approved PA, you’re almost certainly hitting a deductible, a specialty-tier coinsurance, a claim processing error, or a plan-design cost-sharing structure that makes “covered” functionally useless. The fix is usually to chase the cost-sharing structure, not the PA.
“My PA for Wegovy was approved, but… it would cost $1300.”
“Wegovy is covered for $30 with prior authorization.”
Anecdotal cost accounts. Not typical results or a guarantee of any specific price.
What “approved” actually means on a PA letter
A PA approval is a clinical determination — not a statement about the dollar amount you’ll pay. Payment depends on four separate things:
- 1. Your deductible status. If you haven’t met your annual pharmacy deductible (often separate from your medical deductible), you may pay the plan’s negotiated price — which can be $1,000+ — until you meet it.
- 2. Your tier and cost-sharing structure. Tier 2 might be a flat $35 copay. Tier 3 might be 30% coinsurance on a $1,300 drug — that’s $390/month. Specialty-tier placement can be 40%+ coinsurance.
- 3. Claim processing errors. Sometimes the PA is on file but the pharmacy claim is rejecting for a different reason — an NDC mismatch, a coverage gap, or a dose change that triggered re-review. These are fixable with a pharmacy call.
- 4. The Novo Nordisk Savings Offer wasn’t applied. For eligible commercially insured patients, the Savings Offer can bring the copay down to as little as $25/month, with a maximum savings of $100/month.³ The pharmacy has to run it alongside your insurance — not every pharmacy does automatically.
The 10-minute triage when the price quote shocks you
- Enroll in the Novo Nordisk Wegovy Savings Offer at NovoCare.com (or text SAVE to 83757). For eligible commercially insured patients, the card applies at the pharmacy counter. Government-insured patients are not eligible.³
- Ask the pharmacist to re-run the claim with your deductible status noted and the Savings Offer applied.
- Call Caremark member services and ask for a cost breakdown: “My PA is approved, my copay shouldn’t be this high — can you tell me exactly what cost-sharing structure is hitting, and whether my deductible applies?”
- Ask HR whether your plan is in the optional $200 weight-management copay tier. If your employer opted in, you should not be paying above $200/month for Wegovy on that design.⁵
- If the cost is real and nothing above fixes it, weigh the NovoCare Pharmacy direct cash-pay option ($349/month for the injection, $399/month for Wegovy HD, $149–$299/month for the pill depending on dose).³
Not an affiliate link — this is the official enrollment page.
Ro membership: $39 first month, then $149/mo ongoing — or as low as $74/mo with annual plan. Medication pricing matches LillyDirect, NovoCare, and TrumpRx.
What to do if your CVS Caremark plan excludes Wegovy or your PA gets denied
First, know what kind of “no” you got
The word “denied” covers four very different situations. The fix depends on which one you’re in.
| Type of denial | What it looks like | Can you fix it? | How |
|---|---|---|---|
| Documentation denial | “Does not meet criteria” — BMI, comorbidity, or program history not documented. | Yes, usually. | Resubmit with complete chart notes and Letter of Medical Necessity. |
| Step therapy denial | “Step therapy not completed” — plan requires trying a lower-tier drug first. | Yes, in most cases. | Request a step-therapy exception, or document prior trials (prior semaglutide use often counts). |
| Clinical criteria denial | “Contraindication” or “not medically appropriate.” | Sometimes. | Peer-to-peer review with your prescriber; sometimes a formulary exception. |
| Plan exclusion | “Plan does not cover this drug category” — weight-loss medications excluded entirely. | No, through appeals. | Switch paths (below). Appealing a category exclusion is wasted time. |
If your plan excludes the weight-loss category, your four real paths
CVS Caremark is a pharmacy benefit manager. Final coverage depends on your specific plan.
Path 1 — The cardiovascular or MASH pathway, if clinically legitimate
If you have established heart disease, or diagnosed MASH with moderate to advanced fibrosis, Wegovy’s FDA-approved use in those conditions is a separate PA pathway that isn’t tied to the weight-loss benefit category. This is not a workaround — it’s a real indication. Talk to your cardiologist, primary care, or GI specialist about whether your clinical history fits the criteria described above.
Path 2 — NovoCare Pharmacy direct
Novo Nordisk’s own direct-to-patient pharmacy. Current self-pay pricing: Wegovy injection $349/month for 0.25–2.4 mg doses (with an introductory offer of $199/month for the first two monthly fills of 0.25 or 0.5 mg for new patients through June 30, 2026); Wegovy HD 7.2 mg is $399/month; the pill is $149/month for 1.5 mg or 4 mg (4 mg at $149 through August 31, 2026, then $199/month) and $299/month for 9 mg and higher.³ Free shipping. The prescription is processed entirely outside your insurance.
Path 3 — A telehealth partner with an insurance concierge
For readers who want a prescription plus help on the insurance side, Ro is a strong fit for Caremark members specifically: free GLP-1 Insurance Coverage Checker, an insurance concierge that handles PA paperwork if coverage is possible, and self-pay access to FDA-approved GLP-1 medications (including Zepbound and Foundayo) if coverage isn’t. Ro membership is $39 for the first month, then $149/month ongoing — or as low as $74/month with an annual plan paid upfront. Medication pricing for FDA-approved GLP-1s matches LillyDirect, NovoCare, and TrumpRx.
Path 4 — Sesame Care self-pay with provider choice
If you’d rather pick your own clinician and pay cash without a membership structure, Sesame Care offers the broadest branded GLP-1 formulary of any major telehealth marketplace (Wegovy, Zepbound, Ozempic, Mounjaro, Foundayo, Saxenda) with Costco member pricing available on some branded products. Best when you already have a Costco membership or want to compare individual providers.
If this page isn’t quite right for your situation:
- Comparing compounded semaglutide? That’s a separate medication class — browse our compounded GLP-1 content.
- Zepbound instead of Wegovy? See our medical necessity letter guide →
- Haven’t picked a medication yet? Take our free 60-second GLP-1 match quiz →
How Medicare, Aetna, Anthem/BCBS, and self-funded plans change the answer
CVS Caremark is the PBM — the plumbing. Your insurer (Aetna, Anthem, Blue Cross Blue Shield) or a self-funded employer owns the policy and decides the benefit design. That’s why two people with “CVS Caremark” on their cards can get opposite answers.
Aetna + CVS Caremark
Aetna is owned by CVS Health, and many Aetna commercial plans use CVS Caremark as their PBM. That usually means the Caremark formulary positioning applies, but Aetna’s public materials are explicit that formularies are plan-specific and subject to change, and large or self-funded employer arrangements can differ substantially.¹³ For a deeper breakdown, see our Aetna Wegovy prior authorization guide →
Anthem / Blue Cross Blue Shield + CVS Caremark
Many Anthem and Blue Cross Blue Shield plans use CVS Caremark as their PBM. In those cases, the Caremark formulary and PA criteria usually apply, but the insurer’s benefit design and the employer’s plan choices determine everything else — tier, copay, whether weight-loss drugs are covered at all. BCBS affiliates vary by state, and some state-level BCBS plans have stricter BMI thresholds than Caremark’s standard criteria. Check your specific plan document.
Self-funded employer plans
If your employer is self-funded (ask HR, or look for language referencing ERISA in your plan documents), the employer has maximum customization over your benefits. Two people at different companies can both have “CVS Caremark on the back of the card” and have completely different rules. This is the single most common reason for the “why does my coworker’s plan cover it but mine doesn’t” confusion:
“CVS Caremark is not your insurance carrier… They are a PBM.”
The employer writes the rules. Caremark administers them. That’s the structure.
Medicare 2026: a different universe
If you have Medicare, most Part D plans do not cover Wegovy for weight loss in 2026. The FDA-approved cardiovascular risk reduction indication is Part D-coverable in some cases, which is the cleanest clinical pathway for Medicare members with established heart disease.
Medicare GLP-1 Bridge — July 1 through December 31, 2026
- • Flat $50 copay per fill on Bridge-covered claims.
- • Bridge claims operate outside normal Part D sponsor coverage-and-payment flow.
- • Bridge payments do not count toward TrOOP (True Out-of-Pocket) or Part D out-of-pocket maximums.
- • Manufacturer coupons and patient-assistance discount programs are not allowed on Bridge claims.
- • Continued 2027 access depends on your Part D plan sponsor opting into CMS’s BALANCE program — it’s plan-by-plan, not a blanket January 2027 turn-on.⁶
Practical takeaway for Medicare members: don’t rely on commercial-plan guidance. If you have established cardiovascular disease, ask your doctor about the Part D CV pathway. See our Medicare and Wegovy guide →
All paths to Wegovy in 2026, side by side
Seven legitimate payment paths. Your answer comes down to whether your CVS Caremark plan covers Wegovy, whether you’re on government insurance, and how much friction you’re willing to absorb for a lower price. Verified pricing as of April 21, 2026.
| Path | Membership / care fee | Medication cost | Who qualifies | Notes |
|---|---|---|---|---|
| Caremark covered + Savings Offer | — | As low as $25/mo (max $100/mo off your copay) | Commercial insurance + covered plan + PA approved | Government insurance not eligible for the Savings Offer³ |
| Caremark covered, no Savings Offer | — | Varies by tier and deductible | Any covered Caremark member | Use Check Drug Cost & Coverage for your specific estimate |
| Caremark optional $200 copay tier | — | Up to $200/mo | Plans that opted into Caremark’s 2026 weight-management tier⁵ | May be excluded from out-of-pocket max |
| Ro | $39 first month, then $149/mo or $74/mo annual | Matches LillyDirect / NovoCare / TrumpRx | Anyone; free Insurance Coverage Checker + insurance concierge | FDA-approved GLP-1 options including Zepbound and Foundayo |
| Sesame Care | Per-visit fee varies by provider | Costco member pricing available on branded GLP-1s | Anyone | Broadest branded formulary on a self-pay marketplace |
| NovoCare Pharmacy — injection | — | $199/mo first 2 fills (new, 0.25/0.5 mg, through 6/30/2026); $349/mo standard; $399/mo HD 7.2 mg³ | Anyone with a valid prescription | Processed outside insurance; free shipping |
| NovoCare Pharmacy — pill | — | $149/mo (1.5 mg; 4 mg through 8/31/2026); $299/mo for 9 mg+³ | Anyone with a valid prescription | Tablet launched January 2026 |
| Retail list price (no coverage, no card) | — | $1,349/mo³ | N/A — almost no one pays this | Reference price only |
Why we built this page and how we verified it
Every other answer on Bing for this query either over-promises (“yes, Caremark covers Wegovy”) or under-explains (“it depends”). Neither is useful if you’re the person trying to figure out your specific plan. We built this page to separate what’s publicly confirmed from what only your plan can tell you, to cite every factual claim, and to date every verification.
¹ Wegovy’s preferred status on Standard Control, Advanced Control, and Value formularies — business.caremark.com/what-we-do/cost-management/formulary/glp-1s.html.
² Caremark’s public statement that ~1/3 of its employer-sponsored book has no weight-loss coverage — same source.
³ Wegovy Savings Offer terms and NovoCare Pharmacy pricing — novocare.com/eligibility/wegovy-savings-card.html; NovoCare Pharmacy Wegovy Price Guide PDF.
⁴ Current PA criteria (initial, renewal, tablet/injection, CV pathway, MASH pathway) — Caremark PA policy document CF_RxCriteria_WEGOVY_4774-C on info.caremark.com.
⁵ Optional 2026 up-to-$200 weight-management copay tier — 2026 GLP-1 Insights Report, business.caremark.com.
⁶ Medicare GLP-1 Bridge July–December 2026 rules, TrOOP, coupon exclusion, BALANCE opt-in — cms.gov Medicare GLP-1 Bridge page.
⁷ No new GLP-1 formulary changes in January 2026 — business.caremark.com formulary strategies page.
⁸ Member-page language that coverage and PA rules depend on the member’s plan — info.caremark.com/dig/pa-forms.
⁹ ePA speed guidance (2–3× faster; under 6 seconds for some automated decisions) — caremark.com/pharmacists-medical-professionals/e-prior-authorization.html.
¹⁰ Wegovy prescribing information (MTC, MEN 2, GLP-1 coadministration) — novocare.com/patient/medicines/wegovy.html.
What we didn’t verify: your specific plan’s tier, copay, deductible status, step-therapy requirements, or whether your employer includes weight-loss drug coverage at all. Those vary plan by plan and must be verified by you — via the Check Drug Cost & Coverage tool, a call to member services with our script, or Ro’s free Insurance Coverage Checker.
We re-verify the data on this page quarterly, and emergency refreshes happen whenever Caremark, Novo Nordisk, or CMS announce a material change.
Frequently asked questions
Does CVS Caremark cover Wegovy for weight loss?
Yes, on Caremark’s Standard Control, Advanced Control, and Value template formularies — Wegovy has been the preferred GLP-1 for weight loss since July 1, 2025 and remains preferred in 2026. But whether your specific employer plan covers it depends on your benefit design; Caremark has said about one-third of its employer-sponsored book of business does not include weight-loss drug coverage.
Does CVS Caremark cover Wegovy tablets in addition to the pen?
Caremark’s current public PA policy (4774-C) includes both Wegovy injection and Wegovy tablets. Whether your specific plan treats the tablet the same as the pen — tier, quantity, PA duration — depends on your plan document, so verify both forms separately if you’re considering the pill.
Does an approved prior authorization guarantee a low copay?
No. A PA approval confirms the medication is clinically authorized under your plan’s rules — it does not determine the dollar amount you’ll pay. Your actual cost depends on your deductible status, tier placement, coinsurance structure, and whether the Novo Nordisk Savings Offer was applied.
Can I submit the Caremark Wegovy prior authorization myself?
No — the PA must be submitted by your prescriber. What you can do is hand your prescriber’s office a complete packet (BMI, comorbidities, six months of program history, any prior medication trials) before the visit, and ask them to submit via electronic prior authorization (ePA) rather than fax.
What BMI do I need for Wegovy approval through CVS Caremark?
Caremark’s public criteria require a BMI of 30 or higher for the standard adult pathway, or a BMI of 27 or higher with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. Documentation must come from your prescriber’s chart.
Why does my coworker’s CVS Caremark plan cover Wegovy but mine doesn’t?
Because CVS Caremark is a pharmacy benefit manager — it administers the rules, but your employer or insurer decides them. Two people with Caremark ID cards can have completely different Wegovy coverage because their employers made different benefit-design choices about whether to include weight-loss medications.
Does Aetna with CVS Caremark cover Wegovy?
Many Aetna commercial plans use CVS Caremark as their PBM and therefore track Caremark’s formulary positioning, but Aetna’s own materials say formularies are plan-specific and large or self-funded employer arrangements can differ. Aetna Medicare plans generally do not cover Wegovy for weight loss in 2026 but may cover it for the FDA-approved cardiovascular risk reduction indication in qualifying cases.
Does Medicare cover Wegovy if CVS Caremark manages my drug benefit?
Most Medicare Part D plans do not cover Wegovy for weight loss in 2026. The FDA-approved cardiovascular risk reduction indication is Part D-coverable in some cases. CMS’s Medicare GLP-1 Bridge runs July–December 2026 at a flat $50 copay that does not count toward TrOOP and does not allow coupons. 2027 Part D access depends on your plan sponsor opting into the BALANCE program.
How long does CVS Caremark take to approve a Wegovy PA?
Caremark says electronic prior authorization is two to three times faster than phone or fax, with some automated decisions delivered in under six seconds. Actual turnaround depends on documentation completeness and whether the request requires manual clinical review. Federal rules require expedited review for medically urgent requests on most commercial and Medicare plans.
Can I appeal a CVS Caremark Wegovy denial?
Yes, most clinical denials can be appealed — documentation denials, step-therapy denials, and clinical criteria denials all have legitimate appeal paths. Plan exclusions, where your employer has excluded the weight-loss drug category entirely, are not appealable through standard channels, because the category is not covered to begin with.
What if Zepbound worked better for me than Wegovy?
Zepbound was removed from CVS Caremark’s Standard Control, Advanced Control, and Value formularies on July 1, 2025. Coverage is still possible through a formulary exception request documenting medical necessity — for example, intolerance to semaglutide or insufficient response on Wegovy.
Does CVS Caremark cover Wegovy for cardiovascular risk reduction?
Caremark’s public 4774-C policy includes a separate PA pathway for Wegovy’s FDA-approved cardiovascular risk reduction indication — Wegovy injection, for adults with established cardiovascular disease plus obesity or overweight (BMI ≥27), without type 2 diabetes, and on guideline-directed management therapy. This pathway can matter on plans that exclude the weight-loss drug category specifically but cover cardiovascular medications broadly.
Still not sure which GLP-1 path fits your plan, diagnosis, and budget?
If CVS Caremark coverage turns out to be a dead end — or if you want a path mapped to your exact situation — take our free 60-second GLP-1 match quiz. It routes you by insurance type, state, budget, and whether you want brand-name or alternative options, and the output is a personalized action plan you can take to your doctor.
No sign-up to see the match. Routes by insurance type, state, and budget.
Related guides
The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. Wegovy® is a registered trademark of Novo Nordisk. CVS Caremark® is a registered trademark of CVS Health. This page is for educational information only and is not medical, legal, or financial advice. Talk to your healthcare provider about whether Wegovy is right for you, and verify coverage with your own plan.
Affiliate disclosure: Some links on this page (including Ro and Sesame Care) are affiliate relationships that pay The RX Index a fee when a reader signs up, at no additional cost to the reader. NovoCare.com links are not affiliate links. Our editorial recommendations reflect verified facts and the match to the search intent, not commission levels.
Last verified: April 21, 2026.